Compare Regeneron Pharmaceuticals Inc (REGN) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Global X Defense Tech ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $750.8 (market cap $76.14B), while Global X Defense Tech ETF trades at $59.75 (market cap $6.29B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 12.1× Global X Defense Tech ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Global X Defense Tech ETF for 44 Days on average.
| REGN | SHLD | |
|---|---|---|
Market Cap | $76.14B | $6.29B |
Volume | 500,239 | 1,133,252 |
Sector | Health | Sector/Thematic |
52-Week High | $852.03 | $78.02 |
52-Week Low | $557.73 | $58.20 |
Typical Hold Time | 107 Days | 44 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
SHLD, the Global X Defense Tech ETF, trades at $58.74, down 2.2% on the day amid a bearish technical signal. The ETF focuses on defense technology and cybersecurity, with recent institutional buying interest noted in filings. However, key financial ratios like P/E and P/S are not available for this ETF, and the overall technical picture is negative, with moving averages and oscillators signaling bearish momentum.
The outlook for SHLD is mixed, with potential tailwinds from rising global defense spending and institutional accumulation, but weighed down by bearish technicals and the absence of clear valuation metrics. Risks include geopolitical shifts and ETF-specific performance versus peers. The investment case hinges on sustained defense budget growth and SHLD's ability to capture tech-driven defense innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
